Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | INBX |
---|---|---|
09:32 ET | 2292 | 15.33 |
09:41 ET | 500 | 15.16 |
09:54 ET | 300 | 15.42 |
09:56 ET | 100 | 15.5 |
10:10 ET | 100 | 15.55 |
10:17 ET | 100 | 15.6 |
10:21 ET | 100 | 15.595 |
10:30 ET | 1200 | 15.59 |
10:33 ET | 100 | 15.65 |
10:50 ET | 100 | 15.91 |
11:06 ET | 100 | 15.93 |
11:13 ET | 4262 | 15.87 |
11:15 ET | 100 | 15.94 |
11:40 ET | 200 | 15.92 |
11:49 ET | 120 | 16.006 |
11:54 ET | 1150 | 16.05 |
11:56 ET | 280 | 16.03 |
11:58 ET | 300 | 16.05 |
12:00 ET | 1680 | 15.97 |
12:02 ET | 200 | 16 |
12:03 ET | 500 | 16.0525 |
12:07 ET | 1188 | 16.01 |
12:12 ET | 581 | 16.005 |
12:30 ET | 200 | 16.045 |
12:32 ET | 300 | 15.94 |
12:34 ET | 100 | 15.94 |
12:52 ET | 316 | 16 |
12:56 ET | 100 | 16.04 |
12:57 ET | 200 | 15.985 |
12:59 ET | 300 | 15.855 |
01:12 ET | 100 | 15.915 |
01:32 ET | 100 | 15.9799 |
01:51 ET | 200 | 15.98 |
02:08 ET | 432 | 15.905 |
02:13 ET | 100 | 15.915 |
02:24 ET | 100 | 15.98 |
02:26 ET | 100 | 15.935 |
02:27 ET | 100 | 15.87 |
02:49 ET | 200 | 15.83 |
03:21 ET | 276 | 15.71 |
03:27 ET | 1800 | 15.7 |
03:48 ET | 100 | 15.68 |
03:50 ET | 300 | 15.62 |
03:52 ET | 1325 | 15.55 |
03:56 ET | 4100 | 15.575 |
03:57 ET | 600 | 15.58 |
03:59 ET | 11141 | 15.52 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Inhibrx Biosciences Inc | 237.5M | 0.1x | --- |
Immutep Ltd | 346.0M | -9.1x | --- |
Zura Bio Ltd | 236.0M | -8.2x | --- |
Abeona Therapeutics Inc | 241.7M | -2.8x | --- |
Trevi Therapeutics Inc | 244.6M | -8.6x | --- |
Zentalis Pharmaceuticals Inc | 230.1M | -1.4x | --- |
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist, being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $237.5M |
---|---|
Revenue (TTM) | $1.9M |
Shares Outstanding | 14.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $121.21 |
Book Value | $0.92 |
P/E Ratio | 0.1x |
Price/Sales (TTM) | 128.2 |
Price/Cash Flow (TTM) | 0.1x |
Operating Margin | 89,188.29% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.